ArticleThe Journal of infectious diseases2021
Report of the National Institutes of Health SARS-CoV-2 Antiviral Therapeutics Summit.
Article in The Journal of infectious diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Treatment with Remdesivir of Children with SARS-CoV-2 Infection: Experience from a Clinical Hospital in Romania.Life (Basel, Switzerland) · 2024Article
- Article
- Entropy driven cooperativity effect in multi-site drug optimization targeting SARS-CoV-2 papain-like protease.Cellular and molecular life sciences : CMLS · 2023Article
- Observing inhibition of the SARS-CoV-2 helicase at single-nucleotide resolution.Nucleic acids research · 2023Article
- Molnupiravir's mechanism of action drives "error catastrophe" in SARS-CoV-2: A therapeutic strategy that leads to lethal mutagenesis of the virus.Molecular therapy. Nucleic acids · 2023Article
- Accelerating antiviral drug discovery: lessons from COVID-19.Nature reviews. Drug discovery · 2023Review
- Inhibition of the SARS-CoV-2 helicase at single-nucleotide resolution.bioRxiv : the preprint server for biology · 2022Article
- A Versatile Class of 1,4,4-Trisubstituted Piperidines Block Coronavirus Replication In Vitro.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Mutations in the SARS-CoV-2 RNA-dependent RNA polymerase confer resistance to remdesivir by distinct mechanisms.Science translational medicine · 2022Article
- Therapeutics for the treatment of coronavirus disease 2019 in children and adolescents.Clinical and experimental pediatrics · 2022Article
- Article
- Marine mollusc extracts-Potential source of SARS-CoV-2 antivirals.Reviews in medical virology · 2022Review
- Suite of TMPRSS2 Assays for Screening Drug Repurposing Candidates as Potential Treatments of COVID-19.ACS infectious diseases · 2022Article
- COVID-19 therapeutics: Challenges and directions for the future.Proceedings of the National Academy of Sciences of the United States of America · 2022Review
- Oral antivirals for the prevention and treatment of SARS-CoV-2 infection.AIDS reviews · 2022Article
- A Suite of TMPRSS2 Assays for Screening Drug Repurposing Candidates as Potential Treatments of COVID-19.bioRxiv : the preprint server for biology · 2022Article
- Review on molnupiravir as a promising oral drug for the treatment of COVID-19.Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2022Review
- Structures and functions of coronavirus replication-transcription complexes and their relevance for SARS-CoV-2 drug design.Nature reviews. Molecular cell biology · 2022Review
- Druggable targets and therapeutic development for COVID-19.Frontiers in chemistry · 2022Review
- SARS-CoV-2: Current trends in emerging variants, pathogenesis, immune responses, potential therapeutic, and vaccine development strategies.International immunopharmacology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
42 authors.
Funding
Abstract
The NIH Virtual SARS-CoV-2 Antiviral Summit, held on 6 November 2020, was organized to provide an overview on the status and challenges in developing antiviral therapeutics for coronavirus disease 2019 (COVID-19), including combinations of antivirals. Scientific experts from the public and private sectors convened virtually during a live videocast to discuss severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) targets for drug discovery as well as the preclinical tools needed to develop and evaluate effective small-molecule antivirals. The goals of the Summit were to review the current state of the science, identify unmet research needs, share insights and lessons learned from treating other infectious diseases, identify opportunities for public-private partnerships, and assist the research community in designing and developing antiviral therapeutics. This report includes an overview of therapeutic approaches, individual panel summaries, and a summary of the discussions and perspectives on the challenges ahead for antiviral development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.